| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_888a35753ede716db93f09086405c8eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- |
| filingDate |
2002-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2da4b5d1e174356c6f4506204133e6ea |
| publicationDate |
2002-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-02066033-A1 |
| titleOfInvention |
Epothilone derivatives for the treatment of refractory tumors |
| abstract |
A method of treating tumors in a mammal, especially a human that have demonstrated resistance to oncology with taxane oncology agents is disclosed. The method is effective where the tumor has initially been unresponsive to taxane therapy or has developed resistance during the course of treatment. The method comprising the administration of an epothilone derivative selected from those represented by formula I:[chemical drawing]The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that both[chemical drawing]The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that both are efficacious upon oral administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE41990-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007525519-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7091193-B2 |
| priorityDate |
2001-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |